[Epcoritamab (relapsed or refractory diffuse large B-cell lymphoma) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen
Record ID 32018005576
German
Original Title:
Epcoritamab (DLBCL)
Details
Project Status:
Completed
URL for project:
https://www.iqwig.de/projekte/g23-27.html
Year Published:
2024
URL for published report:
https://www.iqwig.de/download/g23-27_epcoritamab_bewertung-35a-absatz-1-satz-11-sgb-v_v1-0.pdf
English language abstract:
There is no English language summary available
Publication Type:
Full HTA
Country:
Germany
MeSH Terms
- Lymphoma, Large B-Cell, Diffuse
- Antineoplastic Agents
- Receptors, Chimeric Antigen
- Antibodies, Bispecific
Keywords
- Epcoritamab
- Lymphoma – Large B-Cell – Diffuse
- Health Care Costs
- Epidemiology
Contact
Organisation Name:
Institute for Quality and Efficiency in Health Care (IQWiG)
Contact Address:
IQWiG, Siegburger Str. 237, 50679 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851
Contact Email:
berichte@iqwig.de
Copyright:
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.